Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Fernandez

Allergy & Immunology Cleveland, OH Medical Doctor

NPI 1649495003 CMS profile 381644

9500 Euclid Ave, Cleveland, OH 44195

Open in the dashboard

General payments

$179,278

233 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Fernandez of Cleveland, OH is reported in the CMS Open Payments database as having received $179,278 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,474 43
2024 General $73,540 105
2023 General $12,274 19
2022 General $20,822 33
2021 General $20,343 19
2020 General $10,170 4
2019 General $6,655 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Fernandez
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to James Fernandez were reported at $35,474. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year James Fernandez Allergy & Immunology median Middle half National median
2019 $6,655 $594 $163–$1,512 $163
2020 $10,170 $426 $106–$1,233 $114
2021 $20,343 $638 $157–$1,708 $132
2022 $20,822 $790 $205–$1,961 $149
2023 $12,274 $852 $220–$2,147 $160
2024 $73,540 $865 $203–$2,267 $164
2025 $35,474 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $153,571 204 payments
  2. Merck Sharp & Dohme Corporation $10,180 13 payments
  3. Shire North American Group Inc $5,725 8 payments
  4. Genzyme Corporation $5,165 4 payments
  5. Genentech USA, Inc. $2,645 1 payment
  6. Invivyd Inc $1,750 1 payment
  7. Amgen Inc. $143 1 payment
  8. Novartis Pharmaceuticals Corporation $99 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $133,143 43 payments
  2. Consulting Fee $24,500 19 payments
  3. Travel and Lodging $18,780 95 payments
  4. Food and Beverage $2,855 76 payments
Products named General payments · program years 2019–2025
  1. CUVITRU $65,789 84 payments
  2. HYQVIA $60,884 81 payments
  3. CINRYZE $4,248 6 payments
  4. DUPIXENT $2,873 3 payments
  5. Xolair $2,645 1 payment
  6. PEMGARDA $1,750 1 payment
  7. UPLIZNA $143 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

182

Median for Allergy/ Immunology: 449

Drug cost

$659,887

Median for Allergy/ Immunology: $169,700

Branded share of claims

73.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 29 $221,017
Hyqvia Igg/Hyaluronidase,recombinant Brand 25 $162,529
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 19 $122,467
Xolair Omalizumab Brand 30 $98,663
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 16 $53,368
Azithromycin Generic 25 $1,056
Azelastine Hcl Generic 11 $369
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $248
Hydroxychloroquine Sulfate Generic 13 $169

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$13,851

Medicare's payments for the services billed

Medicare patients

103

Average age 66

Services billed

166

80 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 47%
Depression 31%
Osteoporosis 31%
Diabetes 30%
COPD 30%
Chronic kidney disease 27%
Ischemic heart disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $45,945
$45,945 25 —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $7,640
$7,640 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record